As we previously foreshadowed, the innovation patent system has been given its end dates:
25 August 2021: last date to lodge innovation patents; and
25 August 2029: date on which last of the innovation patents will expire.
On 26 February 2020 the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019 (the “new Act”) received the final assent by the Governor-General after passing the House of Representatives earlier this month.
The new Act specifies that the abolition of the innovation patent system comes into effect 18 months after the date of assent (yesterday). There is a transition period of 18 months starting from 26 February 2020 in which new innovation patents may be lodged, but from 26 August 2021, no new innovation patents can grant, as their date of grant would be on or after the date of commencement of the new Act.
The only exception is that a pending standard patent application may be converted to an innovation patent application, or a divisional innovation patent may be lodged from it, provided the filing date of the standard patent application is before 26 August 2021 (the commencement date of the new Act).
As innovation patents have an inextensible 8‑year term, all innovation patents, including those derived from a pending standard patent application filed before commencement of the new Act, will expire by 25 August 2029.
With effect from today, the new Act also makes amendments to the test for a compulsory licence under part 2 of the Patents Act. Under Part 2, the Federal Court may order a patentee to grant a license (a “Compulsory Licence”) to another party to exploit the invention in certain circumstances. No Compulsory Licence has been granted to date, and the provisions have been the subject of recent scrutiny, including in the recent Productivity Commission Inquiry Report No 61 2013, Compulsory Licensing of Patents.
Under the new Act, a Court must apply a ‘public interest’ test in replacement of the ‘reasonable requirements of the public’ test. According to the accompanying Explanatory Memorandum, the new test is meant focus the test on ‘community wide welfare’ rather than the interests of the Australian industry. When considering a Compulsory Licence, the new Act states (new s132B):
“The court may order a compulsory licence to be granted if certain conditions are met, including that demand in Australia for the invention is not being met on reasonable terms, authorisation to exploit the invention is essential to meet that demand and it is in the public interest to grant the licence. If the person seeking the compulsory licence is the patentee of another invention and is seeking the licence to exploit that other invention, the court must also be satisfied that the other invention involves an important technical advance of considerable economic significance on the original invention.”
Jennifer Enmon PhD, JD
Special Counsel Patent Attorney (Registered in US, AU & NZ; EU Qualified) Trade Mark Attorney, AU & NZ
Jennifer has been advising clients on life sciences related patent matters for over 15 years.
Jennifer is a registered Patent Attorney in Australia, New Zealand and the United States and is a qualified Patent Attorney in Europe. She is also a registered Trade Mark Attorney in Australia and New Zealand.
Executive Lawyer, Patent Attorney & Trade Mark Attorney
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators, and in IAM Strategy 300: The World's Leading IP Strategists. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.